COSCIENS Biopharma Inc
TSX:CSCI

Watchlist Manager
COSCIENS Biopharma Inc Logo
COSCIENS Biopharma Inc
TSX:CSCI
Watchlist
Price: 2.9 CAD -2.03% Market Closed
Market Cap: 9.4m CAD

COSCIENS Biopharma Inc
Net Issuance of Common Stock

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

COSCIENS Biopharma Inc
Net Issuance of Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
COSCIENS Biopharma Inc
TSX:CSCI
Net Issuance of Common Stock
-$135k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Theratechnologies Inc
TSX:TH
Net Issuance of Common Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Repare Therapeutics Inc
NASDAQ:RPTX
Net Issuance of Common Stock
$110k
CAGR 3-Years
-90%
CAGR 5-Years
-79%
CAGR 10-Years
N/A
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Net Issuance of Common Stock
-$114.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-48%
X
Xenon Pharmaceuticals Inc
NASDAQ:XENE
Net Issuance of Common Stock
$15.7m
CAGR 3-Years
-70%
CAGR 5-Years
-34%
CAGR 10-Years
-10%
Spectral Medical Inc
TSX:EDT
Net Issuance of Common Stock
CA$1.8m
CAGR 3-Years
174%
CAGR 5-Years
-21%
CAGR 10-Years
-11%
No Stocks Found

COSCIENS Biopharma Inc
Glance View

Market Cap
9.2m CAD
Industry
Biotechnology

COSCIENS Biopharma Inc is a CA-based company operating in Biotechnology industry. The company is headquartered in Toronto, Ontario. COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The firm is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.

CSCI Intrinsic Value
7.08 CAD
Undervaluation 59%
Intrinsic Value
Price

See Also

What is COSCIENS Biopharma Inc's Net Issuance of Common Stock?
Net Issuance of Common Stock
-135k USD

Based on the financial report for Sep 30, 2025, COSCIENS Biopharma Inc's Net Issuance of Common Stock amounts to -135k USD.

What is COSCIENS Biopharma Inc's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 1Y
-82%

Over the last year, the Net Issuance of Common Stock growth was -82%.

Back to Top